Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464879 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator
A Phase 2 study of Hypogonadal Males, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01464879 is a Phase 2 study of Hypogonadal Males that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01464879, a Phase 2 study of Hypogonadal Males, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 clinical trial in adult hypogonadal males with baseline morning serum testosterone concentrations \<300 ng/dL. The purpose of this study is to evaluate the pharmacokinetics of FE 999303, delivered using an applicator in comparison to hand application
Conditions Studied
Interventions
- DRUG Testosterone Gel (FE 999303)
Study Locations (1)
New York
- AccuMed Research Associates - Garden City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464879
The ClinicalTrials.gov registry entry for NCT01464879 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadal Males appearing as the primary indexed condition, and to 1 intervention - of which Testosterone Gel (FE 999303) is the first listed.
NCT01464879 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01464879 about?
NCT01464879 is a clinical study titled "A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator". This is a Phase 2 clinical trial in adult hypogonadal males with baseline morning serum testosterone concentrations \<300 ng/dL. The purpose of this study is to evaluate the pharmacokinetics of FE 999303, delivered using an applicator in comparison to hand application
What is the current status of trial NCT01464879?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-12. Estimated completion is 2012-05.
What conditions does trial NCT01464879 study?
This clinical trial studies the following conditions: Hypogonadal Males.
What interventions are being tested in trial NCT01464879?
The interventions under investigation include: Testosterone Gel (FE 999303) (DRUG).
Who is sponsoring clinical trial NCT01464879?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01464879 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadal Males
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.